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TREATMENT OF DERMAL GYSTICERCOSIS WITH
PRAZIQUANTEL ("). A NEW CESTOCIDAL AGENT
Miroslau Constante BARANSKI (t)
SIJMMARY
Twenty adult patients presenting dermal cysticercosis without cerebral or
ocular involvement were treated with praziquantel. The first eleven cases receiv-
ed 60 rng,¡hglday and the last nine cases B0 mglkg/d4y. rn both groups the
daily dose was split into three oral intakes 4 to 6 hours apart and the drug
administration lasted for 6 consecutive days. The latter group of patients alsogot dexamethasone, 3 mg daily, from one day before until four days after the
treatment period with praziquantel. The drug proved. to be r00vo efficacious
as demonstrated histopatholqgically by the death of the cysticerci of Taenia so-lium (Çysticercus cellulosae) in serial biopsies taken from the 2nd week on
aft'er the end of treatment, as well as clinically by the steady disappearence of
the dermal nodules during the 6 months following the therapy. Tolerance oî
praziquantel was good as the incidence and severity of side-effects were not Íe-
levant. The drug safety was confi¡meci through laboratory tests which failed. to
detect any abnor'rrral findings related to the hematopoietic, liver and kidney
functions.
UDC 6t6.995.1
INTRODUCTION
Praziquantel, an heterocyclic isoquinoline
derivative, is a new synthetic cornpound highly
active in experimental and human infections
caused by cestodes 1,8,72,73.74. It acts against
Cysticærcus bovis, the larval stage of Taenia
saginata, in naturally infected calves as well as
a,gainst Cysticercus cellulosae, the larval stage
of Taenia solium, in naturally infected pigs2,s,rs.
Extensive pharmacological and toxicological
studies had demonstrated the tolerance and sa-
fety of praziquantel in all tested animal spe-
cies, including controlled trials involving health
volunteers 4'7.
This clinical trial was carried out with the
aim of assessing the efficacy of this new cesto-
cidal agent in the treatment of human dermal
cysticercosis caused by Cysticercus cellulosae.
Trial subjecús and Methods
All twenty patients were treated at the De-
partment of Infectious and Parasitic Diseases,
Medicai School, Federal University of Paraná,
Curitiba, B¡azil. Thirteen cases were admitted
to the Hospital during the treatment perÍod
whereas seven cases were treated at the out-
patient clinic. Praziquantel was administered
per os for six consecutive days. The daily dose
was split into three intakes 4 to 6 hours apart.
The first 11 patients received 60 mg,4<g,/day and
the last nine patients half that dose. This se-
cond group also received 1 mg of dexametha-
sone t.i.d. starting one day prior to the prazi-
quantel intake. The corticoid administration
was maintained until four days after finishing
the treatment with praziquantei. The daily
dose of dexamethasone wâs gradttally decreas-
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Numbet
of
de¡mal
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Before
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4to 9
No.
rAD!DI
Dis¿ribution of dermal nodules
10 to 19
20 to 29
-iJ Number of patients
30 or more
1 month
No.
Number of
demal nodules
30.0
Total (in 20 câses)
(o/o')
Minimum
10.0
Maximm
After t¡eatment
3 months
Reduction
Before
treatment
TÁ.BLE II
Therapeutical response
to the drug administration, there was a single
remaining nodule and; one case initiâIlJ¡ with
25 had two nodules left. These remanent nodu_
les were smaller and had a harder consistency
than at the begining but they were still painless
and moveable. Comparing 60 ând 30 mg/kg/day
no statisticalþ significant difference was found.
between the two doses at the 6th month after
therapy.
The biopsy taken two weeks after the end
of treatment already revealed a disintegrated
cysticercus. Macroscopically one sees a shrunk
gelatinous cream-like mass of soft consistency.
Looking through the microscope, the tegument
is disrupted no lor¡ger making it possible to
identify its three layers. InsÍde the vesicle the
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6 months
No.
?0.0
lst month
(o/o)
13.1
After treatment
3rd month
G7.60/o
scolex is detached from the collum and d.epri-
ved of hooks and suckers. The dead parasite is
surrounded by a conspicuous lymphoplasmoci
tÍc inflammatory reaction ,with eosinophils also
present Fig. 3.
One month after treatment the macro- and
microscopic aspects are similar but the proces-
ses of degeneration and reabsorption of the cys-
ticercus are more advanced and signs of chro-
nic inflammatory and fibrotic reactions start
to appear Fig. 4.
The biopsy repeated on the third month
following the therapy shows the dead cysticer-
cus reduced to a lenticular tuberculum of hard
consistency. Under the microscope one obser-
6th month
85.90/o
o.2
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ves signs of chronic inflammation 
- 
fibroblast
in radial arrangement and giant cells t¡pical
of foreign body granuloma 
- 
and fibrosis in-
duced by the death of the parasite Fig. 5.
In the serum, prior to the treatment, the
complernent fixation was positive in 14 patients
(mean and standard deviation, 7 :h 4.6 units)
and the indirect hem4gglutination in 12 patients
(mean and standard deviation, 1: 163 t 1: 159).
In six cases both reactions were negative. On
the third month after therapy the complement
fixation contìnued to be positive in the same
L4 cases but the mean value diminished to
1.1 I 0.2 units. The indirect.hemagglutination
became negative in 5 cases and its mean titer
decreased to 1.34 a 1;9, Taþle III.
-45.9 %
After treatment
GRAPIIIC 1-REDUCTION OF DERMAL NODULES FOLLOWING
PRAZIAUANTEL ADMINISTRATION
Regarding the occurrence of adverse drug
reactions, only eight cases reported untoward
effects. Abdominal pain or disconfort was the
most common complaint (in 3 cases) then nau-
sea (in 2) and vomiting, general malaise, dizzi-
ness, drowsiness, headache (in 1). These symp-
toms started during the first 3 days of drug
intake and lasted for about 6 days. \¡/hilst 7
patients treated with 60 mg/kg/day cornplained
of side-effects, just 2 of those who received 30
mg/kg/day had cornplaints. However, there
was no statisticalþ significant difference
between the tolerance of both doses, Table IV.
It was found no abnormalities in the labo-
ratof,y results indicative of toxic praziquantel
upon ùhe hematopoietic lÍver and kidney func-
tions.
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